16.0 Abstract: Hormone Responsive Cancers Program The overarching goal of the Hormone Responsive Cancers (HRC) Program of UMGCC is to reduce morbidity and mortality from cancers of hormone-responsive tissues. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Therapeutic strategies against hormone-responsive tumors—identify new agents to target malignancies that remain responsive to hormone manipulation; Theme 2: Mechanisms of innate and acquired hormone resistance—identify and target the mechanisms that confer de novo or acquired resistance to hormone manipulation; and Theme 3: Invasion and metastasis— identify the mechanisms that promote tumor dissemination and identify therapeutic strategies to target these mechanisms. The HRC Program has 47 members representing 16 academic departments and 5 schools/colleges of the University of Maryland. Members of the program conduct cancer-focused research that receives $7.1 million total annual funding, including $3.4 million from NCI and $2.6 million from other peer-reviewed sources. In addition, HRC Program members receive over $1 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, HRC members authored 407 cancer-related publications, of which 30 percent resulted from intraprogrammatic and 23 percent from interprogrammatic collaborations. Twenty-two percent of the publications represent collaborations with external investigators. Research efforts of HRC faculty are supported by extensive use of the BSS, FCSS, GSS, ISS, PBSS, and TLSS.